Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.
In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH. By integrating diagnostic and therapeutic approaches, the company aims to offer a comprehensive solution for disease management, from early identification to targeted treatment.
Founded in 1999, Genfit has evolved from an early-stage research venture into a global biopharmaceutical entity with operations spanning Europe and North America. The company maintains research facilities in Lille and collaborates with academic institutions and industry partners to advance its clinical programs. Over the years, Genfit has completed multiple phases of clinical trials, contributing valuable data to the understanding of liver disease progression and treatment response.
Genfit’s leadership team is led by Chief Executive Officer Pascal Prigent, who brings extensive experience in biotechnology and global clinical development. Under his direction, the company continues to expand its clinical portfolio and pursue strategic partnerships aimed at accelerating the delivery of novel therapies to patients worldwide.
AI Generated. May Contain Errors.
Free GNFTF Stock Alerts